SCHEMBL9983667

SCHEMBL9983667

CN1C(C(=O)c2cccc(Cl)c2)=C(O)c2ccccc2S1(=O)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.53
PTGES O14684 1/20 0.51
USP2 O75604 2/20 0.48
LMNA P02545 1/20 0.48
KDR P35968 1/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2C9 P11712 3/20 0.48
CYP2C19 P33261 3/20 0.48
POLB P06746 2/20 0.48
KDM4E B2RXH2 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
ALOX15 P16050 1/20 0.48
NFKB1 P19838 1/20 0.48
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
BLM P54132 1/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48
MAPT P10636 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9984528 0.93 PTGES (0.53) HSD11B1PTGESUSP2LMNAKDR
SCHEMBL9984157 0.88 HSD11B1 (0.55) HSD11B1USP2LMNAKDRCYP3A4
SCHEMBL9983065 0.88 PTGES (0.57) HSD11B1PTGESUSP2LMNAKDR
SCHEMBL9983452 0.86 HSD11B1 (0.54) HSD11B1USP2LMNAKDRCYP3A4
SCHEMBL9983936 0.86 PTGES (0.53) HSD11B1PTGESUSP2LMNAKDR
SCHEMBL9983651 0.86 HSD11B1 (0.56) HSD11B1PTGESUSP2LMNAKDR
SCHEMBL9983440 0.85 HSD11B1 (0.56) HSD11B1USP2LMNAKDRCYP3A4
SCHEMBL9983832 0.85 PTGES (0.53) HSD11B1PTGESUSP2LMNAKDR
SCHEMBL9983583 0.85 HSD11B1 (0.53) HSD11B1USP2LMNAKDRCYP3A4
SCHEMBL15673690 0.85 PTGES (0.62) HSD11B1PTGESUSP2LMNAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187438-B2 Derivatives of benzothiazines, preparation thereof and application thereof as drugs PIERRE FABRE MEDICAMENT (FR) 2015-11-17 US claimed
EP-2403840-B1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS PF MEDICAMENT (FR) 2014-05-14 EP claimed
US-20110319326-A1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS PIERRE FABRE MEDICAMENT (FR) 2011-12-29 US claimed
EP-2403840-B1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS PF MEDICAMENT (FR) 2014-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319326-A1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS HSD11B1, CYP11B1, HSD17B11 HSD11B1 1/4885PTGES 578/4885USP2 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.